Dashboard
Manage Tickers

NVCT Nuvectis Pharma, Inc.

Nasdaq nuvectis.com


$ 6.20 $ 0.19 (3.16 %)    

Friday, 24-Oct-2025 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 6.2
$ 6.11
$ 5.61 x 25
$ 6.77 x 25
$ 5.96 - $ 6.40
$ 4.44 - $ 11.80
197,270
na
157.83M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nuvectis-to-present-nxp900-clinical-safety-and-fat1-tumor-data-at-aacr-nci-eortc-2025-international-conference
Nuvectis To Present NXP900 Clinical Safety...
10/16/2025 12:02:38

nuvectis-launches-phase-1b-trial-of-nxp900-in-advanced-solid-tumors-and-resistant-nsclc
Nuvectis Launches Phase 1b Trial Of NXP900...
08/11/2025 20:44:08

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid ...

nuvectis-pharma-q2-eps-030-misses-026-estimate
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0....
08/05/2025 11:41:00

hc-wainwright--co-maintains-buy-on-nuvectis-pharma-lowers-price-target-to-10
HC Wainwright & Co. Maintains Buy on Nuvec...
08/04/2025 14:58:34

HC Wainwright & Co. analyst Joseph Pantginis maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and lowers the price tar...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 12:08:18

nuvectis-pharma-shared-final-clinical-data-update-from-the-phase-1b-study-of-nxp800-in-recurrent-platinum-resistant-arid1a-mutated-ovarian-cancer-and-reported-on-the-progress-towards-the-initiation-of-the-phase-1b-program-for-nxp900
Nuvectis Pharma Shared Final Clinical Data...
07/31/2025 11:48:13

As part of the NXP800 Phase 1b study, 17 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer were treate...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/27/2025 12:10:46

nuvectis-pharma-q1-eps-027-misses-025-estimate
Nuvectis Pharma Q1 EPS $(0.27) Misses $(0....
05/06/2025 12:03:07

Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-buy-on-nuvectis-pharma-raises-price-target-to-15
HC Wainwright & Co. Reiterates Buy on Nuve...
04/30/2025 11:37:55

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and raises the price ta...

nuvectis-pharma-unveils-poster-presentation-highlights-for-nxp900-from-the-2025-american-association-for-cancer-research-meeting-including-phase-1a-dose-escalation--update-for-treatment-with-nxp900
Nuvectis Pharma Unveils Poster Presentatio...
04/29/2025 20:30:42

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic...

maxim-group-initiates-coverage-on-nuvectis-pharma-with-buy-rating-announces-price-target-of-17
Maxim Group Initiates Coverage On Nuvectis...
04/02/2025 17:14:52

Maxim Group analyst Naz Rahman initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and announces Price Tar...

laidlaw--co-initiates-coverage-on-nuvectis-pharma-with-buy-rating-announces-price-target-of-19
Laidlaw & Co. Initiates Coverage On Nuvect...
03/17/2025 12:18:22

Laidlaw & Co. analyst Yale Jen initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and announces Price...

hc-wainwright--co-maintains-buy-on-nuvectis-pharma-lowers-price-target-to-11
HC Wainwright & Co. Maintains Buy on Nuvec...
02/25/2025 16:48:27

HC Wainwright & Co. analyst Joseph Pantginis maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and lowers the price tar...

nuvectis-pharma-2024-net-loss-19m
Nuvectis Pharma 2024 Net Loss $19M
02/25/2025 13:17:25

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
02/05/2025 21:05:51

nuvectis-pharma-prices-135m-public-offering-of-27m-shares-at-500share
Nuvectis Pharma Prices $13.5M Public Offer...
02/05/2025 14:03:56

nuvectis-pharma-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed
Nuvectis Pharma Announces Proposed Public ...
02/04/2025 21:36:50

Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precis...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
02/03/2025 12:05:43

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
11/14/2024 21:10:05

nuvectis-pharma-ceo-says-increased-dose-intensity-needed-to-drive-more-efficacy-from-ovarian-cancer-lead-drug
Nuvectis Pharma CEO Says Increased Dose In...
11/14/2024 19:23:38

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety wit...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION